Endovia Health Sciences: amends equity line beneficial ownership limit to 9.99%

What happened On Oct 15, 2026, Endovia Health Sciences, Inc. entered into a letter agreement with C/M Capital Master Fund, LP pursuant to which the parties agreed to amend the Securities Purchase Agreement dated Sep 19, 2025 to increase the beneficial ownership limitation percentage from 4.99% to 9.99%, effective immediately. The parties also waived the notice requirements in the Purchase Agreement, and the Letter Agreement supersedes inconsistent provisions. The Purchase Agreement was originally filed as Exhibit 10.3 to the Company’s Form 8-K filed on Sep 25, 2025. The Investor’s resales of shares under the Purchase Agreement are registered on the Company’s Form S-1 (File No. 333-298112), which was declared effective on Aug 24, 2026. The filing states that the information in this Current Report on Form 8-K is incorporated by reference into, and updates and supersedes the applicable information in, the Registration Statement.

Key details

• Amendment date: Oct 15, 2026.
• Purchase Agreement date: Sep 19, 2025; originally filed Sep 25, 2025.
• Beneficial ownership limit increased from 4.99% to 9.99%, effective immediately.
• Registration statement: Form S-1 File No. 333-298112, declared effective Aug 24, 2026.

Why it may matter This report is Item 1.01, entry into a material definitive agreement, describing an amendment to the Company’s equity line (the Purchase Agreement) that raises the beneficial ownership limitation and waives certain notice requirements. The report also includes Item 9.01 for exhibits. The filing does not show why the insider traded or why the company acted.